Dexedrine dopes Paladin’s results

Share on linkedin
Share on twitter
Share on facebook
Share on email
Share on print

Paladin (Tor., PLB, $ 11.49) should surpass the $ 100 million (M $) in revenue in 2009 through the acquisition of exclusive marketing rights in Canada’s Dexedrine, a drug from GlaxoSmithKline. 

Read this French article on Les Affaires…

About the Author(s):

Post Author

Your wealth matters.

Sign up to our Newsletter for updates on when we publish new insights.